Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage

The Food and Drug Administration has approved Novo Nordisk’s weight loss drug, Wegovy, for use in reducing the risk of serious cardiovascular complications in adults with obesity and heart disease. This decision could expand insurance coverage for the drug and similar obesity treatments. Wegovy, along with its counterpart Ozempic, has gained popularity in the weight loss industry due to its effectiveness in helping patients lose weight. Wegovy is the first weight loss medication to receive expanded approval for this purpose. The drug is recommended to be used alongside a reduced calorie diet and increased physical activity. Novo Nordisk expects to receive approval for Wegovy in the EU as well.